Tango Therapeutics
NASDAQ: TNGXBoston, US · Founded 2020 · Delaware corporation · 4 known investors
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
Biotech
Founders & leadership
AC
Adam CrystalExecutive Officer
DB
Daniella BeckmanExecutive Officer
DB
Douglas BarryExecutive Officer
AH
Alan HuangExecutive Officer
AD
Aaron DavisDirector
BW
Barbara WeberExecutive Officer, Director
KP
Kanishka PothulaDirector
LA
Lesley Ann CalhounDirector
AB
Alexis BorisyDirector
RH
Reid HuberDirector
JK
John KetchumDirector
MP
Malte PetersDirector
Investors · 4
Competitors · 8
by search overlapPatSnap70 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Diabetes Prevention Program54 shared keywords
Tango48 shared keywords
Czytaj więcej41 shared keywords
Cowles_Investments_StemCentrx38 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Tangoanalytics37 shared keywordsTango provides a software platform for managing commercial real estate portfolios across corporate, retail, and other enterprises. The platform covers site selection, lease management, energy and sustainability tracking, workplace optimization, and project coordination.
Thepharmaletter35 shared keywords
Ziprecruiter35 shared keywords
Companies competing with Tango Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$15MraisedOct 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedOct 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John KetchumDirector
- Barbara WeberExecutive Officer, Director
- Malte PetersDirector
- Kanishka PothulaDirector
- Lesley Ann CalhounDirector
- Mace RothenbergDirector
- Alexis BorisyDirector
- Adam CrystalExecutive Officer
- Daniella BeckmanExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80MraisedAug 2023 · 17 investors · PharmaceuticalsRule 506(b)
▶$80MraisedAug 2023 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lesley Ann CalhounDirector
- Adam CrystalExecutive Officer
- Douglas BarryExecutive Officer
- Mace RothenbergDirector
- Alexis BorisyDirector
- Alan HuangExecutive Officer
- Barbara WeberExecutive Officer, Director
- Daniella BeckmanExecutive Officer
- Malte PetersDirector
- Reid HuberDirector
- Aaron DavisDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Mizuho raises Tango Therapeutics stock price target on combo data By Investing.cominvesting.com · 2026
- JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.comng.investing.com · 2026
- Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board - Simply Wall St Newssimplywall.st · 2026
- Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby - Simply Wall St Newssimplywall.st · 2026
- Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target is $27 | MarketScreenermarketscreener.com · 2026